Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

Molecular and cellular bases of chronic myeloid leukemia.

Chen Y, Peng C, Li D, Li S.

Protein Cell. 2010 Feb;1(2):124-32. doi: 10.1007/s13238-010-0016-z. Epub 2010 Feb 6. Review.

2.

BCR-ABL kinase is dead; long live the CML stem cell.

Perl A, Carroll M.

J Clin Invest. 2011 Jan;121(1):22-5. doi: 10.1172/JCI43605. Epub 2010 Dec 13.

3.

Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.

Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16870-5. Epub 2006 Oct 31.

4.

Role of Pten in leukemia stem cells.

Peng C, Chen Y, Li D, Li S.

Oncotarget. 2010 Jun;1(2):156-60.

6.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
7.

[Research advance on molecular genetics of CML blast crisis].

Zhu HQ, Zhang S, Liu XL.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2008 Feb;16(1):217-21. Review. Chinese.

PMID:
18315935
8.

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M.

N Engl J Med. 2001 Apr 5;344(14):1038-42. Erratum in: N Engl J Med 2001 Jul 19;345(3):232.

9.

PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia.

Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL Jr.

Blood. 2005 May 15;105(10):3995-4003. Epub 2005 Jan 18.

10.

Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.

Mak DH, Schober WD, Chen W, Konopleva M, Cortes J, Kantarjian HM, Andreeff M, Carter BZ.

Mol Cancer Ther. 2009 Sep;8(9):2509-16. doi: 10.1158/1535-7163.MCT-09-0386. Epub 2009 Sep 1.

11.

A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.

Ma L, Shan Y, Bai R, Xue L, Eide CA, Ou J, Zhu LJ, Hutchinson L, Cerny J, Khoury HJ, Sheng Z, Druker BJ, Li S, Green MR.

Sci Transl Med. 2014 Sep 3;6(252):252ra121. doi: 10.1126/scitranslmed.3009073.

12.

Impact of additional chromosomal aberrations and BCR-ABL kinase domain mutations on the response to nilotinib in Philadelphia chromosome-positive chronic myeloid leukemia.

Kim TD, Türkmen S, Schwarz M, Koca G, Nogai H, Bommer C, Dörken B, Daniel P, le Coutre P.

Haematologica. 2010 Apr;95(4):582-8. doi: 10.3324/haematol.2009.014712. Epub 2009 Dec 16.

13.

Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia.

Giles FJ, Cortes JE, Kantarjian HM.

Curr Mol Med. 2005 Nov;5(7):615-23. Review.

PMID:
16305488
14.

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC.

Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22.

PMID:
23433665
15.

Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop.

Roumiantsev S, Shah NP, Gorre ME, Nicoll J, Brasher BB, Sawyers CL, Van Etten RA.

Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5. Epub 2002 Jul 29.

16.

BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors.

Copland M, Pellicano F, Richmond L, Allan EK, Hamilton A, Lee FY, Weinmann R, Holyoake TL.

Blood. 2008 Mar 1;111(5):2843-53. Epub 2007 Dec 21. Erratum in: Blood. 2008 May 1;111(9):4830.

17.

Targeted chronic myeloid leukemia therapy: seeking a cure.

Fausel C.

J Manag Care Pharm. 2007 Oct;13(8 Suppl A):8-12. Review.

18.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R.

Blood. 2004 Apr 15;103(8):3167-74. Epub 2003 Dec 11.

19.

Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.

Abe A, Minami Y, Hayakawa F, Kitamura K, Nomura Y, Murata M, Katsumi A, Kiyoi H, Jamieson CH, Wang JY, Naoe T.

Int J Hematol. 2008 Dec;88(5):471-5. doi: 10.1007/s12185-008-0221-1. Epub 2008 Nov 29.

20.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639

Supplemental Content

Support Center